Kamada

Company Overview

Snapshot

Founded in December 1990 by David Tsur, Kamada operates with 201–500 employees. The company has raised a total of $150 million across 7 funding rounds from 2 investors.

Business overview

Kamada is a plasma-derived protein therapeutics company specializing in the extraction and purification of proteins from human plasma using its proprietary platform technology. The company develops and commercializes a portfolio of FDA-approved products, including GLASSIA for Alpha-1 Antitrypsin (AAT) deficiency and KEDRAB for rabies immune globulin. Kamada serves the health tech and life sciences sectors, with products in late-stage clinical development for conditions such as type 1 diabetes, GvHD, and lung transplant rejection.

Strategic signal

In September 2023, Kamada announced the expansion of its plasma collection operations in Texas with a new site in Houston. This strategic move signals the company's commitment to strengthening its supply chain and increasing its capacity for plasma-derived therapeutics, which is crucial for its product development and commercialization efforts in the biopharmaceutical market.

Company Intelligence Q&A

What was a significant operational expansion for Kamada in 2023?

In September 2023, Kamada announced the expansion of its plasma collection operations in Texas with the opening of a new site in Houston.

What was a key strategic transaction for Kamada in 2021?

In November 2021, Kamada announced a strategic transformational transaction to position itself as a global leader in the plasma-derived hyperimmune market through the acquisition of a portfolio of four FDA-approved commercial products.

What was a notable acquisition made by Kamada in 2021?

In February 2021, Kamada acquired an FDA-licensed plasma collection center from Blood and Plasma Research, Inc. in Texas, USA.

When did Kamada go public on NASDAQ?

Kamada went public on NASDAQ in June 2008.

Which investor participated in Kamada's funding rounds?

FIMI Opportunity Funds participated in multiple funding rounds for Kamada, including a lead investment in May 2023.